You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Potent, non-competitive excitatory amino acid transporter (EAAT) blocker. Preferentially inhibits glutamate-induced [3H]D-aspartate release (IC50 = 1.2 μM) rather than [3H]L-glutamate uptake (IC50 = 16.9 μM). Moderately selective; displays no affinity for NMDA and metabotropic glutamate receptors, and low affinity for AMPA and kainate receptors (IC50 values are 35 and 45 μM respectively).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 172.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||29.05 mL||145.23 mL||290.46 mL|
|1 mM||5.81 mL||29.05 mL||58.09 mL|
|2 mM||2.9 mL||14.52 mL||29.05 mL|
|10 mM||0.58 mL||2.9 mL||5.81 mL|
References are publications that support the biological activity of the product.
Conti et al (1999) Synthesis and enantiopharmacology of new AMPA-kainate receptor agonists. J.Med.Chem. 42 4099 PMID: 10514280
Funicello et al (2004) Dissociation of [3H]glutamate uptake from glutamate-induced [3H]D-Aspartate release by 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrrolo[3,4-d]isoxazole-4-carboxylic acid and 3-hydroxy-4,5,6,6a-tetrahydro-3aH-pyrro Mol.Pharmacol. 66 522 PMID: 15322243
Conti et al (1999) Synthesis of new bicyclic analogues of glutamic acid. Tetrahedron 55 5623
If you know of a relevant reference for (±)-HIP-B, please let us know.
View Related Products by Product Action
Keywords: (±)-HIP-B, (±)-HIP-B supplier, Potent, non-competitive, EAAT, inhibitors, inhibits, Excitatory, Amino, Acid, Transporters, GLAST, GLT-1, Glutamate, Monoamine, Neurotransmitter, 2218, Tocris Bioscience
Citations for (±)-HIP-B
Citations are publications that use Tocris products.
Currently there are no citations for (±)-HIP-B. Do you know of a great paper that uses (±)-HIP-B from Tocris? Please let us know.
Reviews for (±)-HIP-B
There are currently no reviews for this product. Be the first to review (±)-HIP-B and earn rewards!
Have you used (±)-HIP-B?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.